Octagam 20grams Inj, 200ml

• Live virus vaccines (e.g., measles, mumps, rubella, varicella): IVIG can interfere with the immune response to these vaccines. Vaccination should be delayed for at least 3 months, and up to 1 year for measles, after IVIG administration.

• Loop diuretics: Increased risk of acute renal failure, especially with sucrose-containing IVIG products (Octagam is sucrose-free, but caution still advised in susceptible patients).
• Nephrotoxic drugs: Increased risk of renal dysfunction when co-administered with other nephrotoxic agents.

• Headache
• Fever
• Chills
• Nausea
• Vomiting
• Rash
• Flushing
• Dizziness
• Fatigue
• Muscle cramps
• Back pain
• Chest pain
• Dyspnea
• Signs of thrombosis (e.g., pain, swelling, discoloration of limb, sudden shortness of breath, chest pain, neurological deficits)
• Signs of acute renal failure (e.g., decreased urine output, edema, fatigue)
• Signs of aseptic meningitis (e.g., severe headache, nuchal rigidity, photophobia, fever, nausea, vomiting)

Category C. Animal reproduction studies have not been conducted. It is not known whether Octagam can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Octagam should be given to a pregnant woman only if clearly needed. However, IVIG is often used in pregnancy for certain autoimmune conditions (e.g., ITP, recurrent pregnancy loss) and is generally considered relatively safe.

L2 (Safer). Human IgG is excreted into breast milk and may contribute to the transfer of protective antibodies to the neonate. No adverse effects on the breastfed infant are expected. Consider the benefits of breastfeeding along with the mother's clinical need for Octagam.

Dosing for PI, ITP, and CIDP is weight-based and similar to adults. Use with caution in neonates and infants due to potential for renal dysfunction and thrombosis, especially with higher concentrations or rapid infusion rates. Ensure adequate hydration.

Use with caution due to increased risk of thrombosis and acute renal failure. Ensure adequate hydration. Administer at the minimum dose and infusion rate practicable. Monitor renal function closely. Patients over 65 years of age are at higher risk for thrombotic events.

• Always ensure adequate hydration before, during, and after IVIG infusion to minimize the risk of renal dysfunction and headache.
• Infuse slowly initially, especially for the first infusion or in patients at high risk for adverse reactions, and gradually increase the rate if tolerated.
• Pre-medication (e.g., acetaminophen, antihistamines, corticosteroids) may be considered for patients with a history of infusion-related reactions.
• Monitor vital signs frequently during the infusion, particularly during the first hour.
• Be vigilant for signs of thrombosis (e.g., stroke, MI, DVT, PE) and acute renal failure, especially in high-risk patients.
• Octagam is sucrose-free, which may reduce the risk of osmotic nephrosis compared to sucrose-containing IVIG products, but renal dysfunction can still occur.
• Patients with selective IgA deficiency with known antibodies to IgA are at increased risk of severe hypersensitivity reactions, including anaphylaxis. Octagam contains trace amounts of IgA.

• Other Immune Globulin Intravenous (IVIG) brands (e.g., Gammagard, Privigen, Flebogamma, Gamunex-C, Panzyga, Asceniv)
• Subcutaneous Immune Globulin (SCIG) for PI (e.g., Hizentra, Cuvitru, Xembify, HyQvia)
• Immunosuppressants (e.g., corticosteroids, rituximab, azathioprine, mycophenolate mofetil) for autoimmune conditions where IVIG is used.
• Splenectomy (for refractory ITP)